Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash & Equivalents (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Cash & Equivalents for 8 consecutive years, with $37.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 24.21% to $37.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $37.9 million, a 24.21% increase, with the full-year FY2024 number at $28.7 million, down 54.41% from a year prior.
  • Cash & Equivalents was $37.9 million for Q3 2025 at Whitehawk Therapeutics, down from $144.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $227.6 million in Q1 2025 to a low of $28.7 million in Q4 2024.
  • A 5-year average of $84.6 million and a median of $62.9 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 73.81% in 2022, then skyrocketed 323.15% in 2025.
  • Whitehawk Therapeutics' Cash & Equivalents stood at $149.0 million in 2021, then crashed by 73.81% to $39.0 million in 2022, then surged by 61.17% to $62.9 million in 2023, then plummeted by 54.41% to $28.7 million in 2024, then soared by 32.3% to $37.9 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Cash & Equivalents are $37.9 million (Q3 2025), $144.9 million (Q2 2025), and $227.6 million (Q1 2025).